Who Supplies Paclitaxel to India from HONG KONG

To import finished pharmaceutical formulations containing Paclitaxel into India, the foreign manufacturer must obtain a No Objection Certificate (NOC) from the Central Drugs Standard Control Organisation (CDSCO). The importer must possess a valid Importer License issued by the Directorate General of Foreign Trade (DGFT). The product must be registered with CDSCO, which involves submitting Form CT-20/40/41, along with the Certificate of Pharmaceutical Product (CoPP) and a Certificate of Good Manufacturing Practice (GMP). The registration process typically takes 6–12 months. Paclitaxel formulations under HS Code 30049044 are subject to these requirements.

Imported Paclitaxel formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data must adhere to International Council for Harmonisation (ICH) guidelines for Zone IV. Port inspection by customs drug inspectors is mandatory to verify product authenticity and quality.

Between 2024 and 2026, CDSCO has updated import regulations to streamline the registration process for foreign pharmaceutical products, reducing approval times by 20%. The Production Linked Incentive (PLI) scheme, introduced in 2024, offers incentives to domestic manufacturers, potentially affecting the import demand for finished formulations. Bilateral agreements with Hong Kong have facilitated smoother trade, including mutual recognition of GMP certifications.

India imports finished Paclitaxel formulations due to the high demand for patented and branded products not manufactured domestically. Specific dosage forms, such as injectable solutions, are often sourced from abroad. The domestic capacity is limited, leading to a dependency on imports. The Indian market for Paclitaxel formulations is valued at approximately $100 million annually.

The Basic Customs Duty (BCD) for HS Code 30049044 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, totaling 1%. The Integrated Goods and Services Tax (IGST) is 12%. Anti-dumping duties may apply if the product is deemed to be dumped in the Indian market. Exemptions under FTAs may reduce duties. The total landed duty percentage varies based on the product's CIF value and applicable exemptions.

India sources finished Paclitaxel formulations from Hong Kong due to its competitive advantages, including adherence to international quality standards and the availability of specialized dosage forms. Hong Kong's share in India's Paclitaxel import market is approximately 5%. Other suppliers include China, Germany, and the United States, but Hong Kong's proximity and trade agreements with India make it a preferred source.

India imports finished Paclitaxel formulations from Hong Kong due to the availability of patented formulations and specialized dosage forms not produced domestically. Hong Kong's adherence to international quality standards and efficient regulatory processes make it a reliable source.

Compared to China, the European Union, and the United States, Hong Kong offers competitive pricing, high-quality products, and favorable trade relations with India. Its proximity and established trade agreements further enhance its appeal as a sourcing destination.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, importers should diversify suppliers, monitor currency trends, stay updated on regulatory changes, conduct regular quality audits, and maintain buffer stock.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance.
5. 5Regulatory Compliance: Stay informed about changes in import regulations and ensure all necessary certifications are in place.

1. 1Obtain a valid Importer License from DGFT.
2. 2Secure a No Objection Certificate (NOC) from CDSCO.
3. 3Register the product with CDSCO, submitting Form CT-20/40/41.
4. 4Provide a Certificate of Pharmaceutical Product (CoPP) and Certificate of Good Manufacturing Practice (GMP).
5. 5Ensure compliance with all applicable import regulations under the Drug and Cosmetics Act.

1. 1Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Certificate of Good Manufacturing Practice (GMP).
4. 4Drug Master File (DMF) for the active pharmaceutical ingredient.
5. 5Stability data adhering to ICH guidelines for Zone IV.
6. 6Free Sale Certificate indicating the product is freely sold in the country of origin.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors collect samples for testing at CDSCO-approved laboratories. Batch testing is mandatory to verify compliance with Indian standards. If a batch fails, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance. Common quality issues from Hong Kong include labeling discrepancies and minor packaging defects.